Evidence map›Paper›PMID 22551038›Full record

ArticleClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases2012

Multidrug-resistant (MDR) Klebsiella pneumoniae clinical isolates: a zone of high heterogeneity (HHZ) as a tool for epidemiological studies.

M S Ramirez, G Xie, S H Marshall, K M Hujer, P S G Chain, R A Bonomo, M E Tolmasky

Abstract read
In one paragraph

Article in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Carbapenemases: TransformingBiomolecules · 2020
    Review
  5. SmallFrontiers in microbiology · 2019
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

M S RamirezDepartment of Biological Science, Center for Applied Biotechnology Studies, California State University Fullerton, Fullerton, CA 92831-3599, USA.
G Xie
S H Marshall
K M Hujer
P S G Chain
R A Bonomo
M E Tolmasky

Funding

Understanding ceftazidime resistance in SHV B-LactamasesR01AI063517 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A. · 2005 to 2023
$4.9M
DEALING WITH ANTIBIOTIC RESISTANCE--ANTISENSE TECHNOLOGYR15AI047115 · NIAID · CALIFORNIA STATE UNIVERSITY FULLERTON · PI TOLMASKY, MARCELO E · 2000 to 2022
$1.8M
NIAID NIH HHS 2R15AI047115NIAID NIH HHS R01 AI063517NIAID NIH HHS R01 AI063517-01NIAID NIH HHS R15 AI047115
6 · The paper itself

Abstract

Comparison of genome-wide, high-resolution restriction maps of Klebsiella pneumoniae clinical isolates, including an NDM-1 producer, and in silico-generated restriction maps of sequenced genomes revealed a highly heterogeneous region we designated the 'high heterogeneity zone' (HHZ). The HHZ consists of several regions, including a 'hot spot' prone to insertions and other rearrangements. The HHZ is a characteristic genomic area that can be used in the identification and tracking of outbreak-causing strains.

Indexed as

DNA, BacterialDrug Resistance, Multiple, BacterialPolymorphism, GeneticDisease OutbreaksHumansKlebsiella InfectionsKlebsiella pneumoniaeMicrobial Sensitivity TestsMolecular EpidemiologyMolecular TypingDNA, Bacterial

Identifiers

PMID22551038
PMCPMC3377791

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.